Claims
- 1. A compound represented by Formula I:
- 2. The compound or pharmaceutically acceptable salt according to claim 1, wherein at least one of the R1 groups is a racemic, L-, or D-amino acid group —C(O)CHNH2R4, wherein R4 is a substituted or unsubstituted alkyl, and wherein the remaining R1 groups are H; R2 is OR5 or N(R6)2, wherein R5 is independently selected from H or alkyl, and wherein R6 is independently H, substituted or unsubstituted alkyl, cycloalkyl, or together with nitrogen forms a substituted or unsubstituted heterocycloalkyl ring.
- 3. The compound or pharmaceutically acceptable salt according to claim 2, wherein at least one of the R1 groups is a L-amino acid group —C(O)CHNH2R4, wherein R4 is a substituted or unsubstituted alkyl, and wherein the remaining R1 groups are H; R2 is OR5 or N(R6)2, wherein R4 is a substituted alkyl, and wherein R6 is independently H or substituted or unsubstituted alkyl.
- 4. The compound or pharmaceutically acceptable salt according to claim 3, wherein at least one of the R1 groups is a L-amino acid group —C(O)CHNH2R4, wherein R4 is —CH(CH3)2, and wherein the remaining R1 groups are H; and R2 is OH.
- 5. The compound or pharmaceutically acceptable salt according to claim 1, selected from the group consisting of:
- 6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound represented by Formula I:
- 7. The pharmaceutical composition according to claim 6, wherein at least one of the R1 groups is a racemic, L-, or D-amino acid group —C(O)CHNH2R4, wherein R4 is a substituted or unsubstituted alkyl, and wherein the remaining R1 groups are H; R2 is OR5 or N(R6)2, wherein R5 is independently selected from H or alkyl, and wherein R6 is independently H, substituted or unsubstituted alkyl, cycloalkyl, or together with nitrogen forms a substituted or unsubstituted heterocycloalkyl ring.
- 8. The pharmaceutical composition according to claim 7, wherein at least one of the R1 groups is a L-amino acid group —C(O)CHNH2R4, wherein R4 is a substituted or unsubstituted alkyl, and wherein the remaining R1 groups are H; R2 is OR5 or N(R6)2, wherein R4 is a substituted alkyl, and wherein R6 is independently H or substituted or unsubstituted alkyl.
- 9. The pharmaceutical composition according to claim 8, wherein at least one of the R1 groups is a L-amino acid group —C(O)CHNH2R4, wherein R4 is —CH(CH3)2, and wherein the remaining R1 groups are H; and R2 is OH.
- 10. The pharmaceutical composition according to claim 6 that is selected from the group consisting of:
- 11. A method of modulating immune cytokine activities in a patient comprising:
providing a compound or pharmaceutically acceptable salt of formula I according to claim 1; and treating a patient in need thereof with the compound or pharmaceutically acceptable salt.
Parent Case Info
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/333,460, filed on Nov. 27, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60333460 |
Nov 2001 |
US |